A San Diego biotech looking to double up on the power of antibody-drug conjugates with fewer toxicities has patched together a $137 million Series B from a group of blue-chip investors. The seven-employee startup, called Sidewinder Therapeutics, plans to make its mark by simultaneously engaging two targets and “overcoming fundamental limitations in the first-gen ADCs,” CEO Eric Murphy said in an interview. That includes avoiding off-target toxicities that arise when ADC payloads spill into the b

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. April 07, 2026 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil® (rem

First-in-class TET2 activator targets DNA damage response in GBM and other cancers Strong preclinical efficacy, brain penetration, and safety pro clinical advancement Study led by world-leading glioblastoma investigators, including Dr. Roger Stupp Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma (GBM) and ot

April 7, 2026 -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today the initiation of the dose expansion phase in their clinical study evaluating spevatamig in combination with chemotherapy for the treatment of biliary tract cancer (BTC), following dose-limiting toxicity (DLT) clearance at two dose levels. Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin

April 7, 2026 -- ATLATL Innovation Center (hereinafter referred to as "ATLATL"), a global innovation platform for life science research and development, announced an agreement with Daiichi Sankyo to leverage ATLATL's multi-regional innovative R&D network and expertise in the Asia-Pacific biotech sector to help Daiichi Sankyo identify high-quality R&D platform technologies and accelerate the transformation and implementation of innovative science in order to potentially bring new treatment option

April 7, 2026 -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg and 10 mg. The U.S. FDA has approved Lupin's Dapagliflozin Tablets, 5 mg and 10 mg, as bioequivalent to Farxiga® for the indications in the approved labeling. Lupin Limited is a globa

SK Life Science, Inc. will present multiple posters at the American Academy of Neurology (AAN) Annual Meeting (April 18–22, 2026, Chicago, Illinois) Cenoba mate data includes clinical outcomes, real-world evidence, pharmacokinetics and long-term efficacy New analysis presented at AAN 2026 expands on survey findings first shared during National Epilepsy Awareness Month (November 2025) "Hope, Hesitancy, and Hard Truths" survey examines communication between epilepsy patients and healthcare provide

It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for recent examples). Aashish Manglik But two cancer biologists — Aaron Ring at the Fred Hutchinson Cancer Center and Aashish Manglik at UCSF — believed they could go one layer deeper than others. Even within a single protein target, there could be different ways for a drug to attach. They just needed a systematic way to seek out those small bits on a pr

By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, improving patient throughput, and supporting a more cost-effective and reimbursement-aligned treatment model. April 6, 2026 -- Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), today announced the positive results from its phase 1 clinical study of ALA-3000, a

An investigational medicine that addresses the genetic root cause of BAG3 DCM, AFTX-201 is being evaluated as a treatment for BAG3 DCM in the UPBEAT trial in the U.S. and Canada AFTX-201 is designed using Affinia’s proprietary capsid engineered for efficient cardiac transduction at doses that are 5-10-fold lower than doses of gene therapies using conventional capsids Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno